跳至主要内容
临床试验/CTRI/2024/05/066756
CTRI/2024/05/066756尚未招募Unknown

A randomized placebo controlled study evaluating the effect of calcium and vitamin D supplementation on the progression of dengue fever to dengue shock syndrome and dengue hemorrhagic fever - nil

MILIND RAJ NAGVANSHI0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Patient with acute dengue fever confirmed by lab investigations , all patients wiling to give informed consent, all acute dengue fever patient admitted to medicine wards /CCW/ICU at jnmch

排除标准

  • Age more than 60 yr and pregnant females, patient presenting with dengue shock syndrome and dengue hemorrhagic fever, diagnosed comorbid conditions like known case of Type2DM, syst HTN,cancer,active TB, hyperparathyroidism,hypothyroidism,osteoporosis,CKD,CLD,COPD,CAD,CARDIOMYOPATHY,MALABSORPTION,history of allergy from study medication, patients not giving consent for study

研究者

发起方
MILIND RAJ NAGVANSHI

相似试验

招募中
4 期
Role of repetitive transcranial magnetic stimulation (rTMS) in migraine prophylaxis a randomized control trial
CTRI/2012/04/002545Sanjay Gandhi Postgraduate Institute of Medical Sciences100
进行中(未招募)
1 期
A study to examine the safety, tolerability and effects on abnormal bone formation of REGN2477 in patients with Fibrodysplasia Ossificans ProgressivaFibrodysplasia Ossificans Progressiva (FOP)MedDRA version: 20.0Level: PTClassification code 10068715Term: Fibrodysplasia ossificans progressivaSystem Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2016-005035-33-ITREGENERON PHARMACEUTICALS, INC.44
进行中(未招募)
1 期
A study to examine the safety, tolerability and effects on abnormal bone formation of REGN2477 in patients with Fibrodysplasia Ossificans ProgressivaFibrodysplasia Ossificans Progressiva (FOP)MedDRA version: 20.0Level: PTClassification code 10068715Term: Fibrodysplasia ossificans progressivaSystem Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2016-005035-33-GBRegeneron Pharmaceuticals, Inc.40
进行中(未招募)
1 期
A study to examine the safety, tolerability and effects on abnormal bone formation of REGN2477 in patients with Fibrodysplasia Ossificans ProgressivaFibrodysplasia Ossificans Progressiva (FOP)MedDRA version: 20.0Level: PTClassification code 10068715Term: Fibrodysplasia ossificans progressivaSystem Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2016-005035-33-NLRegeneron Pharmaceuticals, Inc.40
进行中(未招募)
1 期
A study to examine the safety, tolerability and effects on abnormal bone formation of REGN2477 in patients with Fibrodysplasia Ossificans ProgressivaFibrodysplasia Ossificans Progressiva (FOP)MedDRA version: 20.0Level: PTClassification code 10068715Term: Fibrodysplasia ossificans progressivaSystem Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2016-005035-33-ESRegeneron Pharmaceuticals, Inc.44